Randomized Phase II Study of Docetaxel plus Bevacizumab or Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323)

被引：0
|
作者：
Kozuki, Toshiyuki [1 ]
Nogami, Naoyuki [1 ]
Yamashita, Natsumi [2 ]
Shinkai, Tetsu [3 ]
Shukuya, Takehito [4 ,5 ]
Seki, Nobuhiko [6 ]
Kato, Terufumi [7 ]
Satouchi, Miyako [8 ]
Masuda, Noriyuki [9 ]
Watanabe, Koshiro [10 ]
机构：
[1] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
[2] Natl Hosp Org, Shikoku Canc Ctr, Clin Res Ctr, Matsuyama, Ehime, Japan
[3] Shonan East Gen Hosp, Dept Internal Med, Chigasaki, Kanagawa, Japan
[4] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan
[5] Grad Sch Med, Tokyo, Japan
[6] Teikyo Univ, Sch Med, Dept Med Oncol, Tokyo 173, Japan
[7] Kanagawa Cardiovasc & Resp Ctr, Resp Med, Yokohama, Kanagawa, Japan
[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[9] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa, Japan
[10] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
elderly; Clinical Trial in Progress; NSCLC; bevacizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-085
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [41] Phase II Study of Docetaxel-plus-Bevacizumab Combination Therapy in Patients Previously Treated for Advanced Non-squamous Non-small Cell Lung Cancer
    Ohyanagi, Fumiyoshi
    Yanagitani, Noriko
    Kudo, Keita
    Kawano, Yuko
    Sakatani, Toshio
    Tanimoto, Azusa
    Nishizawa, Hironari
    Horiike, Atsushi
    Hagiwara, Sachiko
    Horai, Takeshi
    Nishio, Makoto
    ANTICANCER RESEARCH, 2014, 34 (09) : 5153 - 5158
  • [42] NEJ016: Phase II study of carboplatin and weekly paclitaxel plus bevacizumab followed by bevacizumab for highly selected elderly non-squamous non-small cell lung cancer patients
    Harada, T.
    Miura, S.
    Maemondo, M.
    Iwashima, A.
    Sugawara, S.
    Kobayashi, K.
    Inoue, A.
    Nakagawa, T.
    Takiguchi, Y.
    Watanabe, H.
    Seike, M.
    Ishida, T.
    Terada, M.
    Gemma, A.
    Yoshizawa, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S617 - S617
  • [43] Surufatinib Plus Docetaxel in Patients with Relapsed Advanced Driver-Negative Non-Squamous NSCLC: A Phase Ib/II Study
    Jiang, W.
    He, J.
    Ning, R.
    Zhao, Y.
    Zhou, S.
    Xu, L.
    Wang, H.
    Chen, S.
    Gan, H.
    Lin, J.
    Yu, Q. T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S345 - S345
  • [44] Clinical Efficacy and Tolerability of Bevacizumab in Elderly Patients With Advanced Non-Squamous NSCLC
    Santos, Edgardo S.
    Castillero, Lilibeth
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S200 - S200
  • [45] Final Report of an Open-Label Phase II Trial of Bevacizumab Plus Docetaxel and Gemcitabine in Metastatic, Previously Untreated Non-squamous Non-small Cell Lung Cancer (NSCLC)
    Pennell, N. A.
    Kalmadi, S. R.
    Shapiro, M.
    Daw, H.
    Rodriguez, C.
    Haddad, A.
    Samsa, J.
    Elson, P.
    Ma, P.
    Dowlati, A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S247 - S247
  • [46] Pemetrexed plus Platinum Chemotherapy with or Without Immuno Responses of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusions Therapy in Non-Squamous NSCLC: Descriptive Safety Analysis
    Li, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2084
  • [47] EXPLORATORY SUBSET ANALYSIS IN AFRICAN AMERICANS FROM THE POINTBREAK STUDY (RANDOMIZED PHASE 3 PEMETREXED plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE PEMETREXED plus BEVACIZUMAB VERSUS PACLITAXEL plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIB/IV NONSQUAMOUS NON-SMALL CELL LUNG CANCER)
    Reynolds, Craig
    Patel, Jyoti D.
    Garon, Edward
    Olsen, Mark R.
    Bonomi, Philip
    Govindan, Ramaswamy
    Obasaju, Coleman
    Pennella, Eduardo J.
    Liu, Jingyi
    Guba, Susan C.
    Spigel, David
    Hermann, Robert C.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S562 - S562
  • [48] The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
    Ding, Lingyu
    Liu, Kejun
    Jiang, Zhelong
    Chen, Qi
    Zhou, Ningning
    Liang, Ying
    Gao, Hongfei
    Hong, Xiangchan
    Wu, Haiying
    TUMOR BIOLOGY, 2015, 36 (04) : 2491 - 2499
  • [49] Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
    Santoro, Armando
    Hillerdal, Gunnar N.
    Hoeffkenc, Gert
    Favaretto, Adolfo
    Carrion, Ramon Perez
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Helsberg, Karin
    Soldatenkova, Victoria
    Bourayou, Nawel
    Sorensen, Jens B.
    LUNG CANCER, 2014, 86 (01) : 47 - 53
  • [50] RANDOMIZED PHASE II STUDY OF PEMETREXED V. PEMETREXED/BEVACIZUMAB V. CARBOPLATIN/PEMETREXED/BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER AND POOR PERFORMANCE STATUS
    Lilenbaum, Rogerio
    Hainsworth, John
    Joseph, Matthew
    Shipley, Dianna
    Hagan, Kelly
    Thompson, Dana
    Greco, F. Anthony
    Burris, Howard
    Spigel, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S889 - S890
12345